UK markets open in 1 hour 59 minutes
  • NIKKEI 225

    27,401.58
    +19.02 (+0.07%)
     
  • HANG SENG

    22,257.23
    -431.67 (-1.90%)
     
  • CRUDE OIL

    79.39
    -0.29 (-0.36%)
     
  • GOLD FUTURES

    1,930.70
    +1.30 (+0.07%)
     
  • DOW

    33,978.08
    +28.68 (+0.08%)
     
  • BTC-GBP

    19,139.44
    +307.23 (+1.63%)
     
  • CMC Crypto 200

    538.18
    +21.17 (+4.10%)
     
  • ^IXIC

    11,621.71
    +109.31 (+0.95%)
     
  • ^FTAS

    4,258.97
    +5.62 (+0.13%)
     

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Valo Therapeutics LTD
Valo Therapeutics LTD

HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102.

ValoTx’s VALO-D102 oncolytic adenovirus is a fundamental component of the company’s proprietary PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. The platform utilises a unique technology which creates electrostatic interactions between positively charged, tumour-specific peptides and the negatively charged surface of oncolytic adenoviruses. This allows an adenovirus to be used as an immunogenic carrier for the tumour-specific peptides, creating systemic tumour-targeted killer T-cell responses.

Exothera brings expertise in adenovector and A549 cells with a deep knowledge of state-of-the-art manufacturing technology and DoE-based development tools. Exothera will perform tech transfer, analytical development, and scale-up to initiate manufacturing of clinical material for EU Phase II clinical trials in its GMP facility in Jumet, Belgium - one of the biggest dedicated viral vector manufacturing facilities in Europe. The facility can accommodate projects from development to manufacturing scale.

Hanna Lesch, Chief Technology Officer at Exothera: “Valo Tx’s platform has the potential to turn the tide in the fight against cancer. At Exothera, we are excited to put our extensive viral vector expertise at Valo’s service for the process development and manufacturing of such a revolutionary oncolytic virus-based immunotherapy. We're proud to be one of the leaders laying down the roadmap for viral vector production to deliver exciting new cancer therapies like PeptiCRAd-1.”

Petri Priha, Vice President of CMC at Valo Therapeutics: “We are reinventing cancer immunotherapy to make it more effective and accessible to cancer patients. This important work with Exothera will enable us to develop a large-scale manufacturing process for VALO-D102 to support our future clinical development plans and pave the way for future commercial-scale manufacturing.”

About Valo Therapeutics Oy

Valo Therapeutics Oy is an immunotherapy company that is developing innovative immunotherapy approaches against cancer and infectious disease. The ValoTx lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into targeted tissue-specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV and PeptiVAX, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to oncolytic enveloped viruses in the treatment of multiple forms of cancer, while PeptiVAX is a platform to develop novel, adaptable anti-infective vaccines. A film all about how we are reinventing cancer immunotherapy can be found here.

Website: https://www.valotx.com/

About Exothera SA

Exothera is a viral vector CDMO using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide custom-made process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing and provides QC services and analytical development.

Website: www.exothera.world

Contacts

Valo Therapeutics Oy

Matthew Vaughan

Email: info@valotx.com

Scius Communications (for ValoTx)

Katja Stout

+44 778 943 5990

katja@sciuscommunications.com

Daniel Gooch

+44 774 787 5479

daniel@sciuscommunications.com